Prestige Consumer Healthcare (NYSE:PBH) Price Target Raised to $93.00

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) had its price target upped by Oppenheimer from $87.00 to $93.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Oppenheimer's price target suggests a potential upside of 8.62% from the company's previous close.

Other equities analysts have also issued research reports about the company. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Friday, January 24th. Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a research note on Monday, December 9th. Canaccord Genuity Group boosted their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. DA Davidson boosted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $92.60.

Prestige Consumer Healthcare Stock Performance

NYSE PBH traded down $0.06 on Thursday, reaching $85.62. 276,586 shares of the stock were exchanged, compared to its average volume of 288,972. The firm has a market capitalization of $4.23 billion, a PE ratio of 20.05, a PEG ratio of 2.43 and a beta of 0.50. Prestige Consumer Healthcare has a one year low of $62.35 and a one year high of $88.36. The company's 50-day simple moving average is $79.30 and its two-hundred day simple moving average is $76.05. The company has a current ratio of 3.68, a quick ratio of 2.10 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares of the company's stock, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently made changes to their positions in PBH. JPMorgan Chase & Co. raised its holdings in Prestige Consumer Healthcare by 3.2% in the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company's stock worth $19,630,000 after purchasing an additional 8,533 shares in the last quarter. Geode Capital Management LLC increased its stake in Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company's stock valued at $95,678,000 after purchasing an additional 50,961 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Prestige Consumer Healthcare by 12.9% in the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company's stock worth $708,000 after buying an additional 1,120 shares during the last quarter. Avior Wealth Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 1,570.7% during the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company's stock worth $668,000 after buying an additional 8,042 shares during the period. Finally, Barclays PLC grew its holdings in shares of Prestige Consumer Healthcare by 346.3% during the third quarter. Barclays PLC now owns 92,444 shares of the company's stock valued at $6,665,000 after buying an additional 71,730 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.